Skip to main content

RWCS Highlights - Day 4

Feb 16, 2021 6:42 pm

As another year at RWCS in Maui wrapped up, I’m so thankful I had the opportunity to participate remotely.  Thank you to Drs. Kavanaugh and Martin for providing a needed reprieve from the day to day grind in order learn from some of the best! Here are my day 4 #RWCS2021 pearls.

Novel Therapies Year in Review (RA, SLE, OA) with Alvin Wells, MD, PhD and Roy Fleischmann, MD

  • Voclosporin, modified tacrolimus = no dose adjustment, improved lipid profiling with reduction in DM, no impact on MPA (mycophenolic acid) when used in combo (
  • ADVOCATE trial: Avacopan + CTS or RTX: noninferior to GC at week 26 and superior in sustained remission at week 52. Study also showed significant increase in eGFR in renal disease patient with less CG-related toxicity. A draw back will be price compared to steroids. (Merkel P, et al. EULAR2020, OP0011)

Novel concepts in Pediatric Rheumatology with Susan Shenoi, MD

  • PFAPA: (Soriano A et al. Frontiers in Immunology 2020) stands for:
    • P-eriodic  F-ever  A-phthous ulcers  P-haryngitis and  A-denitis  
    • Usually 1-5 years of age, feversevery 4-6 weeks lasting 1-3 days
    • Resolves by age 6, plus/minus 2 years after onset
    • Tends to cluster in families
    • Treated with prednisone, cimetidine, and tonsillectomy.
    • PFAPA in adults: Cantarini’s criteria:
      • over 16 yo after exclusion of infection, autoimmune, or neoplastic dz
      • Recurrent Fever accompanied by a)erythematous pharyngitis and/or cervical lymphadenitis
      • increased inflammatory markers during attacks
      • symptom-free intervals (Cantarini L et al. Frontiers in Immunology 2017)
    • PFAPA may be on Behcet’s spectrum (Manthiram K et al. PNAS. June 2020)
    • PFAPA associated with increased IL12p70 PFAPA monocytes thus, possible treatments: Apremilast – decreases IL-12p&) and INF-r in monocytes and ustekinumab – anti-IL-12/23 (Manthiram K et al PNAS June 2020)
  • VEXAS: (Beck D et al. NEJM 2020) stands for:
    • V-acuoles   E-1 ubiquitin activating enzyme  X-linked  A-utoinflammatory  S-omatic mutation
    • Ferrada M et al, ACR 2020 #0509 showed some Relapsing Polychondritis patients met VEXAS criteria. Certain risk factors of RP nose/ears, Males > 50 yo, MCV >100, plts < 200 were 100% sensitive and 96% specific for disease
  • Theres a reason for these febrile disorders: Ancient FMF mutations in pyrin that led to increased IL-1Beta gave a survival advantage during the Plague (Yesenia Pestis)

TeleRheumatology Update: Post-COVID, Pre-?? Alvin Wells, MD, PhD

  • Check out One application, one medical license for 28 states. This can improve access for our patients.
The author has no conflicts of interest to disclose related to this subject

Add new comment

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.